Brokers just upgraded the Sonic (ASX:SHL) share price and this other ASX stock to "buy"

Our marker is rallying for a second day but two ASX stocks stand out as leading brokers just upgraded them to "buy" on their earnings outlook.

| More on:
Transurban share price ASX shares upgrade to buy asx 200 share price upgrade to buy represented by hand drawing line under the word upgrade

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Our market is rallying for a second day but two ASX stocks stand out as leading brokers just upgraded them to "buy".

The S&P/ASX 200 Index (Index:^AXJO) gained 0.3% as global investors continued to embrace the "Blue Wave" sweeping the US.

But the prospect of large stimulus measures in the world's biggest economy isn't the only driver for ASX stocks.

Testing ramp-up triggers broker's "buy" upgrade

The latest COVID‐19 outbreaks around the country gave Morgans a reason to upgrade the Sonic Healthcare Limited (ASX: SHL) share price.

Testing for the contagious virus is being aggressively ramped up in Australia as Queensland becomes the latest to implement a lockdown to contain the outbreak.

"We estimate more than 9.3m tests have been conducted in 1HFY21, a c8% uplift in total tests from our prior estimate, with SHL capturing c20% market share," said Morgans. 

"Testing across ROW [rest of world] remains strong, with solid estimated 2QFY21/1QFY21 increases across SHL's the main geographies (US, +67%; Ger, +57%; Switzerland, +206%; Belgium, +97%)."

More tests needed despite vaccines

The more virulent strain from the UK will only add to pressure for more people to be tested and Morgans lifted its earnings forecast for Sonic.

"We have adjusted our FY21-23 estimates based on increased assumptions for COVID-19 testing, with incremental earnings contribution between A$99m and A$375m per annum over the forecast period, representing between 6-20% of operating income," added Morgans.

"We believe investors have not completely appreciated the persistent effects of COVID-19 testing."

The broker upgraded its recommendation on the Sonic share price to "add" from "hold". It also increased its 12-month price target to $37.32 from $34.57 a share.

Broker upgrade shifts this ASX stock to higher gear

Meanwhile, the ARB Corporation Limited (ASX: ARB) share price got a boost after Citigroup upgraded the stock.

The broker changed its recommendation on the four-wheel drive accessories supplier to "buy" from "hold" as it believes ARB's medium-term outlook is improving.

The recovery in auto sales, particularly SUVs, is one positive driver for the group. The broker also believes high savings rates and limited international travel will support discretionary spending in 2021.

Additional tailwinds to drive the ARB share price

Further, the strength of the Australian dollar compared to the Thai Baht will also improve ARB's margins. The group operates factories in Thailand.

Additionally, the government's instant asset write-off should boost demand for ARB's products, while strong US demand for utes bodes well for ARB's export sales.

"Citi's proprietary ARB sales index accelerated to +16% growth in December 2020 up from +10% in November 2020 driven by strong growth in upper large SUV (+122%), large SUV (+16%) and 4×4 sales (+14%)," said Citi.

"However, we may have to wait till 2H21 to observe all the sales benefits from this tailwind as accessories for new SUV/4×4 models may not be readily available due to supply chain constraint."

Citi's 12-month price target on the ARB share price increased to $34.25 from $30.30 a share.

Motley Fool contributor Brendon Lau has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ARB Limited and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cheap Shares

A young female investor with brown curly hair and wearing a yellow top and glasses sits at her desk using her calculator to work out how much her ASX dividend shares will pay this year
Cheap Shares

Why I would invest $10,000 in these cheap ASX shares

Sharp share price falls can create opportunity when business quality remains intact.

Read more »

Scientist with headache, stress and fatigue with woman, overworked with overtime for science breakthrough. Medical research, scientific innovation and senior female, burnout and migraine in lab.
Cheap Shares

Are CSL shares still a bargain at $177?

After a sharp sell-off, expectations have reset. The key question is whether the business has truly changed.

Read more »

A kid stretches up to reach the top of the ruler drawn on the wall behind.
Cheap Shares

2 undervalued ASX shares worth buying today

These quality ASX 200 stocks could offer 50-75% upside.

Read more »

A man thinks very carefully about his money and investments.
Cheap Shares

The 3 best undervalued ASX shares I'd pick up in January

3 high-quality ASX shares look undervalued as short-term concerns create potential long-term opportunities.

Read more »

A group of business people pump the air and cheer.
Cheap Shares

Still under $30, these wealth-builders may not stay cheap for long

Want to buy quality when it is cheap? Check out these options.

Read more »

Two people jump and high five above a city skyline.
Cheap Shares

2 beaten-down ASX shares to consider before they recover

These shares were sold off in 2025. Could they rebound in 2026?

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Cheap Shares

2 ASX shares these experts rate as a buy right now

Experts think these stocks are underrated buys.

Read more »

Woman dining at a table with oversized fork and knife in the hospitality industry.
Cheap Shares

Why I think this ASX small-cap stock is a bargain at $2.55

This stock looks eggcellent value to me.

Read more »